Solid pseudopapillary tumor of the pancreas
Updates to Article Attributes
A solidSolid pseudopapillary tumour (SPT) of pancreas is a rare (usually benign) pancreatic tumour.
Epidemiology
They are extremly rare and thought to account for 1-2% of exocrine pancreatic tumours. They tend to present in young non-Caucasian females around the 2nd and 3rd decades of life.
Clinical presentation
Most patients are asymptomatic at diagnosis. They may occasionally present with a gradually enlarging abdominal mass or vague abdominal pain.
Pathology
The tumours frequently contain varying amounts of necrosis, hemorrhage, and cystic change. Lesions can be large at time of diagnosis (median size ~ 8 cm 2)
Location
There is a greater predilection to occur at pancreatic tail.
Associations
- pancreatic dorsal agenesis - possible association 5
Radiographic features
CT
Usually seen as a well-encapsulated lesion with varying solid and cystic components owing to haemorrhagic degeneration. Following IV contrast administration, enhancing solid areas are typically noted peripherally, whereas cystic spaces are usually more centrally located. Calcifications and enhancing solid areas may be present at the periphery of the mass.
MRI
Typically demonstrates a well-defined lesion. May show a pure solid consistency in ~ 80% of cases 6.
Reported signal characteristics include
-
T1:
- lowlow to heterogeneous signal intensity 1,6 -
T2:
- heterogenousheterogenous to high signal intensity 1,6 - C+ (Gd) - can show heterogenous and slowly progressive enhancement
Treatment and prognosis
While most lesions are benign, ~ 15% can be malignant. Complete resection is associated with long-term survival even in the presence of metastatic disease.
EtymologyHistory and etymology
It was first described by Frantz et.al in 1959 4-5.
See also
-<p>A <strong>solid pseudopapillary tumour (SPT) of pancreas</strong> is a rare (usually benign) pancreatic tumour. </p>-<h4>Epidemiology</h4>-<p>They are extremly rare and thought to account for 1-2% of exocrine pancreatic tumours. They tend to present in young non-Caucasian females around the 2<sup>nd</sup> and 3<sup>rd</sup> decades of life. </p>-<h4>Clinical presentation</h4>-<p>Most patients are asymptomatic at diagnosis. They may occasionally present with a gradually enlarging abdominal mass or vague abdominal pain. </p>-<h4>Pathology</h4>-<p>The tumours frequently contain varying amounts of necrosis, hemorrhage, and cystic change. Lesions can be large at time of diagnosis (median size ~ 8 cm <sup>2</sup>)</p>-<h5>Location</h5>-<p>There is a greater predilection to occur at pancreatic tail.</p>-<h5>Associations</h5>-<ul><li>-<a title="pancreatic dorsal agenesis" href="/articles/pancreatic-dorsal-agenesis">pancreatic dorsal agenesis</a> - possible association <sup>5</sup>-</li></ul><h4>Radiographic features</h4>-<h5>CT </h5>-<p>Usually seen as a well-encapsulated lesion with varying solid and cystic components owing to haemorrhagic degeneration. Following IV contrast administration, enhancing solid areas are typically noted peripherally, whereas cystic spaces are usually more centrally located. Calcifications and enhancing solid areas may be present at the periphery of the mass.</p>-<h5>MRI</h5>-<p>Typically demonstrates a well-defined lesion. May show a pure solid consistency in ~ 80% of cases <sup>6</sup>.</p>-<p>Reported signal characteristics include</p>-<ul>-<li>-<strong>T1</strong> - low to heterogeneous signal intensity <sup>1,6</sup>-</li>-<li>-<strong>T2</strong> - heterogenous to high signal intensity <sup>1,6</sup>-</li>-<li>-<strong>C+ (Gd)</strong> - can show heterogenous and slowly progressive enhancement</li>-</ul><h4>Treatment and prognosis</h4>-<p>While most lesions are benign, ~ 15% can be malignant. Complete resection is associated with long-term survival even in the presence of metastatic disease.</p>-<h4>Etymology</h4>-<p>It was first described by <strong>Frantz</strong> et.al in 1959 <sup>4-5</sup>.</p>-<h4>See also</h4>-<ul><li><a title="Pancreatic neoplasms" href="/articles/pancreatic_neoplasms">pancreatic neoplasms</a></li></ul>- +<p><strong>Solid pseudopapillary tumour (SPT) of pancreas</strong> is a rare (usually benign) pancreatic tumour. </p><h4>Epidemiology</h4><p>They are extremly rare and thought to account for 1-2% of exocrine pancreatic tumours. They tend to present in young non-Caucasian females around the 2<sup>nd</sup> and 3<sup>rd</sup> decades of life. </p><h4>Clinical presentation</h4><p>Most patients are asymptomatic at diagnosis. They may occasionally present with a gradually enlarging abdominal mass or vague abdominal pain. </p><h4>Pathology</h4><p>The tumours frequently contain varying amounts of necrosis, hemorrhage, and cystic change. Lesions can be large at time of diagnosis (median size ~ 8 cm <sup>2</sup>)</p><h5>Location</h5><p>There is a greater predilection to occur at pancreatic tail.</p><h5>Associations</h5><ul><li>
- +<a href="/articles/pancreatic-dorsal-agenesis">pancreatic dorsal agenesis</a> - possible association <sup>5</sup>
- +</li></ul><h4>Radiographic features</h4><h5>CT </h5><p>Usually seen as a well-encapsulated lesion with varying solid and cystic components owing to haemorrhagic degeneration. Following IV contrast administration, enhancing solid areas are typically noted peripherally, whereas cystic spaces are usually more centrally located. Calcifications and enhancing solid areas may be present at the periphery of the mass.</p><h5>MRI</h5><p>Typically demonstrates a well-defined lesion. May show a pure solid consistency in ~ 80% of cases <sup>6</sup>.</p><p>Reported signal characteristics include</p><ul>
- +<li>
- +<strong>T1:</strong> low to heterogeneous signal intensity <sup>1,6</sup>
- +</li>
- +<li>
- +<strong>T2:</strong> heterogenous to high signal intensity <sup>1,6</sup>
- +</li>
- +<li>
- +<strong>C+ (Gd)</strong> - can show heterogenous and slowly progressive enhancement</li>
- +</ul><h4>Treatment and prognosis</h4><p>While most lesions are benign, ~ 15% can be malignant. Complete resection is associated with long-term survival even in the presence of metastatic disease.</p><h4>History and etymology</h4><p>It was first described by <strong>Frantz</strong> et.al in 1959 <sup>4-5</sup>.</p><h4>See also</h4><ul><li><a href="/articles/pancreatic-neoplasms">pancreatic neoplasms</a></li></ul>
Unable to process the form. Check for errors and try again.